Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

A 12-week RCT funded by Mitsubishi Corporation Life Sciences has shown that nicotinamide mononucleotide (NMN) intake has significantly improved certain aspects of muscle mobility, especially gait speed and left grip strength – which the company says presents a “potential therapeutic strategy for sarcopenia”.